Company Filing History:
Years Active: 2021-2025
Title: Innovations in Cancer Treatment by Leah Marie Alabanza
Introduction: Leah Marie Alabanza, a dedicated inventor based in Montgomery Village, MD, has made significant contributions to the field of cancer therapy through her innovative research and invention. With a focus on anti-BCMA immunotherapy, her work has the potential to impact cancer treatment significantly, showcasing the importance of innovation in medicine.
Latest Patents: Leah holds one patent titled "Compositions and methods for treating cancer with anti-BCMA immunotherapy." This patent discloses chimeric antigen receptors containing BCMA antigen binding domains, along with various essential components such as nucleic acids, recombinant expression vectors, host cells, and antigen binding fragments. Additionally, the patent involves pharmaceutical compositions and methods for treating or preventing cancer in a subject, as well as methods for producing chimeric antigen receptor T cells.
Career Highlights: Leah's role at Lentigen Technology, Inc. emphasizes her commitment to advancing cancer treatment technologies. Her focus on innovative therapeutic strategies demonstrates her dedication to improving patient outcomes through scientific discovery.
Collaborations: Throughout her career, Leah has collaborated with esteemed colleagues such as Dina Schneider and Zhongyu Zhu. Together, they contribute to a collaborative environment that fosters innovation and research excellence in the field of immunotherapy.
Conclusion: Leah Marie Alabanza stands out as a pioneering inventor in cancer treatment through her groundbreaking patent on anti-BCMA immunotherapy. Her work at Lentigen Technology, Inc. and collaborations with fellow researchers highlight the vital role of innovation in addressing complex health challenges. As research continues to advance, the impact of her contributions will likely resonate within the medical community and beyond.